# table-interpretation


## Evaluation Set

1. Asfaha, Y., Schrenk, C., Alves Avelar, L. A., Lange, F., Wang, C., Bandolik, J. J., Hamacher, A., Kassack, M. U., & Kurz, T. (2020). Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells. Bioorganic & medicinal chemistry, 28(1), 115108. https://doi.org/10.1016/j.bmc.2019.115108

2. Basso, M., Chen, H. H., Tripathy, D., Conte, M., Apperley, K., De Simone, A., Keillor, J. W., Ratan, R., Nebbioso, A., Sarno, F., Altucci, L., & Milelli, A. (2018). Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. ChemMedChem, 13(3), 227–230. https://doi.org/10.1002/cmdc.201700601

3. Chen, J., Sang, Z., Jiang, Y., Yang, C., & He, L. (2019). Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer. Chemical biology & drug design, 93(3), 232–241. https://doi.org/10.1111/cbdd.13405

4. Kassab, S. E., Mowafy, S., Alserw, A. M., Seliem, J. A., El-Naggar, S. M., Omar, N. N., & Awad, M. M. (2019). Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma. Journal of enzyme inhibition and medicinal chemistry, 34(1), 1062–1077. https://doi.org/10.1080/14756366.2019.1613987

5. Sharma, C., Oh, Y. J., Park, B., Lee, S., Jeong, C. H., Lee, S., Seo, J. H., & Seo, Y. H. (2019). Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction. International journal of molecular sciences, 20(24), 6213. https://doi.org/10.3390/ijms20246213

6. Miao, H., Gao, J., Mou, Z., Wang, B., Zhang, L., Su, L., Han, Y., & Luan, Y. (2019). Design, synthesis and biological evaluation of 4-piperidin-4-yl-triazole derivatives as novel histone deacetylase inhibitors. Bioscience trends, 13(2), 197–203. https://doi.org/10.5582/bst.2019.01055

7. Lv, W., Zhang, G., Barinka, C., Eubanks, J. H., & Kozikowski, A. P. (2017). Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors. ACS medicinal chemistry letters, 8(5), 510–515. https://doi.org/10.1021/acsmedchemlett.7b00012

8. Zhang, Y., Yan, J., & Yao, T. P. (2017). Discovery of a fluorescent probe with HDAC6 selective inhibition. European journal of medicinal chemistry, 141, 596–602. https://doi.org/10.1016/j.ejmech.2017.10.022

9. Negmeldin, A. T., Knoff, J. R., & Pflum, M. (2018). The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. European journal of medicinal chemistry, 143, 1790–1806. https://doi.org/10.1016/j.ejmech.2017.10.076

10. Reßing, N., Marquardt, V., Gertzen, C., Schöler, A., Schramm, A., Kurz, T., Gohlke, H., Aigner, A., Remke, M., & Hansen, F. K. (2018). Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity. MedChemComm, 10(7), 1109–1115. https://doi.org/10.1039/c8md00454d

11. Choi, M. A., Park, S. Y., Chae, H. Y., Song, Y., Sharma, C., & Seo, Y. H. (2019). Design, synthesis and biological evaluation of a series of CNS penetrant HDAC inhibitors structurally derived from amyloid-β probes. Scientific reports, 9(1), 13187. https://doi.org/10.1038/s41598-019-49784-9

12. Debnath, S., Debnath, T., Bhaumik, S., Majumdar, S., Kalle, A. M., & Aparna, V. (2019). Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation. Scientific reports, 9(1), 17174. https://doi.org/10.1038/s41598-019-53376-y

13. Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S. (2018). The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay. Journal of enzyme inhibition and medicinal chemistry, 33(1), 525–535. https://doi.org/10.1080/14756366.2018.1437156

## Development Set

1. Kozikowski, A. P., Shen, S., Pardo, M., Tavares, M. T., Szarics, D., Benoy, V., Zimprich, C. A., Kutil, Z., Zhang, G., Bařinka, C., Robers, M. B., Van Den Bosch, L., Eubanks, J. H., & Jope, R. S. (2019). Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome. ACS chemical neuroscience, 10(3), 1679–1695. https://doi.org/10.1021/acschemneuro.8b00600

2. Lee, H. Y., Fan, S. J., Huang, F. I., Chao, H. Y., Hsu, K. C., Lin, T. E., Yeh, T. K., Lai, M. J., Li, Y. H., Huang, H. L., Yang, C. R., & Liou, J. P. (2018). 5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes. Journal of medicinal chemistry, 61(16), 7087–7102. https://doi.org/10.1021/acs.jmedchem.8b00151

3. Stenzel, K., Hamacher, A., Hansen, F. K., Gertzen, C., Senger, J., Marquardt, V., Marek, L., Marek, M., Romier, C., Remke, M., Jung, M., Gohlke, H., Kassack, M. U., & Kurz, T. (2017). Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines. Journal of medicinal chemistry, 60(13), 5334–5348. https://doi.org/10.1021/acs.jmedchem.6b01538

4. Yu, C. W., Hung, P. Y., Yang, H. T., Ho, Y. H., Lai, H. Y., Cheng, Y. S., & Chern, J. W. (2019). Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer. Journal of medicinal chemistry, 62(2), 857–874. https://doi.org/10.1021/acs.jmedchem.8b01590

## Other Usecase specific docs (not used)

Munster, P., Marchion, D., Bicaku, E., Lacevic, M., Kim, J., Centeno, B., Daud, A., Neuger, A., Minton, S., & Sullivan, D. (2009). Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clinical cancer research : an official journal of the American Association for Cancer Research, 15(7), 2488–2496. https://doi.org/10.1158/1078-0432.CCR-08-1930

Vogl, D. T., Raje, N., Jagannath, S., Richardson, P., Hari, P., Orlowski, R., Supko, J. G., Tamang, D., Yang, M., Jones, S. S., Wheeler, C., Markelewicz, R. J., & Lonial, S. (2017). Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(13), 3307–3315. https://doi.org/10.1158/1078-0432.CCR-16-2526

Lu, C. Y., Chang, Y. C., Hua, C. H., Chuang, C., Huang, S. H., Kung, S. H., Hour, M. J., & Lin, C. W. (2017). Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis. International journal of molecular sciences, 18(5), 954. https://doi.org/10.3390/ijms18050954

Liu, J., Cui, X., Guo, F., Li, X., Li, L., Pan, J., Tao, S., Huang, R., Feng, Y., Ma, L., & Fu, P. (2019). 2-methylquinazoline derivative F7 as a potent and selective HDAC6 inhibitor protected against rhabdomyolysis-induced acute kidney injury. PloS one, 14(10), e0224158. https://doi.org/10.1371/journal.pone.0224158

Tu, Y., Hershman, D. L., Bhalla, K., Fiskus, W., Pellegrino, C. M., Andreopoulou, E., Makower, D., Kalinsky, K., Fehn, K., Fineberg, S., Negassa, A., Montgomery, L. L., Wiechmann, L. S., Alpaugh, R. K., Huang, M., & Sparano, J. A. (2014). A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast cancer research and treatment, 146(1), 145–152. https://doi.org/10.1007/s10549-014-3008-5

Fu, X. H., Zhang, X., Yang, H., Xu, X. W., Hu, Z. L., Yan, J., Zheng, X. L., Wei, R. R., Zhang, Z. Q., Tang, S. R., Geng, M. Y., & Huang, X. (2019). CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression. Acta pharmacologica Sinica, 40(5), 677–688. https://doi.org/10.1038/s41401-018-0108-5

Yee, A. J., Bensinger, W. I., Supko, J. G., Voorhees, P. M., Berdeja, J. G., Richardson, P. G., Libby, E. N., Wallace, E. E., Birrer, N. E., Burke, J. N., Tamang, D. L., Yang, M., Jones, S. S., Wheeler, C. A., Markelewicz, R. J., & Raje, N. S. (2016). Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. The Lancet. Oncology, 17(11), 1569–1578. https://doi.org/10.1016/S1470-2045(16)30375-8

